Drug With 93% Success Rate for Pediatric Cancers Gets FDA Breakthrough Status
A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93% of pediatric patients tested. Most cancer drugs are targeted to specific organs or locations in the body. Larotrectinib is the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in…
Utah Standard News depends on the support of readers like you.
Good Journalism requires time, expertise, passion and money. We know you appreciate the coverage here. Please help us to continue as an alternative news website by becoming a subscriber or making a donation. To learn more about our subscription options or make a donation, click here.
To Advertise on UtahStandardNews.com, please contact us at: ed@utahstandardnews.com.
Comments - No Responses to “Drug With 93% Success Rate for Pediatric Cancers Gets FDA Breakthrough Status”
Sure is empty down here...